Date: 2011-10-11
Type of information: R&D agreement
Compound: Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein
Company: Karyopharm Therapeutics (USA) Katholieke Universiteit Leuven (Belgium)
Therapeutic area: Cancer - Oncology - Autoimmune diseases - Infectious diseases
Type agreement: research - R&D
Action mechanism:
Disease: cancer, autoimmune diseases and viral diseases
Details: Karyopharm Therapeutics has initiated an exclusive collaboration in the area of Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein with the Rega Institute for Medical Research, a part of the Katholieke University of Leuven (K.U.Leuven), Belgium. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease. Karyopharm will work with scientists lead by Dr. Dirk Daelemans of the Laboratory of Virology and Chemotherapy at the Rega Institute on the discovery and development of novel SINE CRM1 inhibitors. Together, the groups will expand the portfolio of Karyopharm’s SINE CRM1 antagonists for the treatment of cancer, autoimmune diseases and viral disorders.
Financial terms: Financial details were not disclosed.
Latest news:
